Core Insights - Certara's software bookings have shown a deceleration, with a 6% year-over-year decline in Q4, impacting the company's revenue growth outlook for 2026, which is projected to be flat to 4% [2][6][4] - The company reported that organic software revenue growth for 2025 was 7%, aligning with internal expectations, while EBITDA margin reached 32%, at the high end of guidance [3][4] - Certara's growth initiatives focus on biosimulation, particularly in quantitative systems pharmacology (QSP), Simcyp, and PBPK services, alongside AI and cloud offerings [5][11][12] Software Bookings and Revenue Outlook - The decline in software bookings is attributed to customer reprioritization and lagging study counts from slower clinical trial starts, which are expected to pressure future bookings [6][4] - Certara's organic trailing-twelve-month software bookings growth rate was approximately 1% for the previous year, indicating a need for improvement in this area [2][6] Services Performance - Certara's services segment has shown low-single-digit growth, averaging around 3% over the last three years, with a strong performance in December suggesting market stability [8][6] - The company noted that services bookings can be volatile, with significant fluctuations observed between quarters [8] Customer Segments and Market Dynamics - Tier-three customers, including biotechs, performed well, benefiting from an easing funding environment, while tier-one customers are expected to show stability despite past volatility [9] - The company anticipates that the reprioritization and headcount reductions affecting tier-one customers are largely behind them, although they may still impact near-term revenue [9] Growth Areas and AI Integration - Demand for model-informed drug development (MIDD) and biosimulation remains strong, with QSP and AI-enabled offerings being key growth areas [11][12] - Certara's acquisition of Vyasa in 2022 has allowed the integration of AI technology into its products, enhancing capabilities and customer value [12][13] Operational Priorities and Capital Allocation - Under new leadership, Certara aims to align its software and services offerings more closely, adopting a customer-centric approach [14] - The company plans to maintain an EBITDA margin of 30% to 32% while investing in R&D, particularly in MIDD and biosimulation, and has identified $10 million in cost avoidance for 2026 [15][16] Industry Trends and Opportunities - The industry is gradually shifting towards alternatives to animal model studies, presenting a significant opportunity for Certara in biosimulation, although adoption may take time due to risk aversion in pharma [17]

Summary of Certara Conference Call Company Overview - **Company**: Certara - **Industry**: Healthcare technology and distribution, specifically focusing on biosimulation and Model-Informed Drug Development (MIDD) Key Points and Arguments Financial Performance - **Q4 Performance**: Revenue and EBITDA were in line with expectations, with organic software revenue growth for 2025 at 7% [3][4] - **EBITDA Margin**: Achieved a high end of the original guidance at 32% [3][4] - **2026 Revenue Guidance**: Projected growth is flat to 4%, influenced by a deceleration in software bookings [4][7] - **Bookings Decline**: Q4 software bookings decreased by 6% year-over-year, attributed to customer dynamics and reduced seat licenses in the Phoenix product [4][5] Market Dynamics - **Customer Behavior**: Noted a shift in customer dynamics, particularly among large pharma clients, impacting software bookings [4][5] - **Services Revenue**: Services revenue has grown at a low single-digit rate (approximately 3%) over the last three years, with a strong December performance [6][7] - **End Market Outlook**: Anticipated stable market conditions with potential tailwinds, particularly in services [9][43] Leadership and Strategy - **New CEO**: Jon Resnick has been appointed, bringing a fresh perspective and a focus on customer-centricity [10][15] - **Operational Changes**: Emphasis on aligning software and services offerings to better meet customer needs [15][16] - **Incentive Structure**: Plans to unify incentives across the organization to enhance collaboration between software and services [17] Product Development and AI Integration - **AI Strategy**: Certara has integrated AI technology from the acquisition of Vyasa, launching Certara IQ for Quantitative Systems Pharmacology (QSP) [22][23] - **Growth Areas**: QSP, Simcyp, and PBPK services are identified as fast-growing segments within the organization [12][30] - **Human in the Loop**: Certara's model requires scientific expertise alongside software, creating a competitive advantage [34] Regulatory and Market Evolution - **Biosimulation Role**: Certara is positioned to lead in biosimulation as the industry shifts away from animal model studies, which are seen as less effective [35][36] - **Market Adaptation**: The company is adapting to changes in disease focus areas among biopharma clients, maintaining flexibility to meet evolving demands [40][41] M&A and Capital Allocation - **M&A Appetite**: Certara is open to pursuing tuck-in acquisitions, supported by a strong balance sheet and cash position [44][45] - **Share Repurchase Program**: The company has initiated a share repurchase program as part of its capital allocation strategy [46] Overall Sentiment - **Optimism for 2026**: Certara expresses excitement about internal changes and operational initiatives that could lead to improved performance [47][48] - **Conservatism in Guidance**: The company has set conservative guidance to build a solid foundation for future growth, reflecting a cautious but optimistic outlook [47][48]

Summary of Certara's Conference Call Company Overview - **Company**: Certara - **Industry**: Healthcare technology and distribution, specifically focusing on biosimulation and drug development Key Financial Highlights - **Q4 Performance**: Revenue and EBITDA were in line with expectations, with organic software revenue growth of 7% for 2025, and EBITDA margin at 32%, which was at the high end of guidance [3][4] - **2026 Revenue Guidance**: Projected revenue growth is flat to 4%, influenced by a 1% organic TTM software bookings and a -6% year-on-year decline in Q4 software bookings [4][5] - **Services Revenue**: Low single-digit growth of about 3% over the last three years, with a strong December in services bookings indicating potential stability in the market [6][7] Market Dynamics - **Customer Dynamics**: Notable deceleration in software bookings attributed to macro customer reprioritization and a decrease in study counts on Pinnacle 21 [4][5] - **End Market Outlook**: Despite challenges, there is an expectation of a stable market with potential tailwinds, particularly in services [7][8] Product and Service Insights - **Software and Services**: Strong demand for Model-Informed Drug Development (MIDD) and biosimulation services, particularly in QSP, Simcyp, and PBPK services [12][13] - **AI Integration**: Certara is integrating AI capabilities into its products, with the launch of Certara IQ for QSP and enhanced functionalities in Phoenix Cloud [26][27] Leadership and Strategic Changes - **New CEO**: Jon Resnick's appointment is expected to bring a customer-centric approach and improve commercial execution [9][15] - **Operational Changes**: Focus on aligning incentives across software and services to enhance customer engagement and operational efficiency [16][17] Research and Development - **Investment in R&D**: Continued investment in R&D is planned, particularly in MIDD and biosimulation, while maintaining EBITDA margins between 30%-32% [19][20] - **Cost Management**: Identified $10 million in cost avoidance to support investments while maintaining financial discipline [21] Future Opportunities - **Biosimulation's Role**: Certara is positioned to lead in the shift towards biosimulation as a replacement for traditional animal model studies, aiming to help biopharma companies reduce R&D costs and time [38][39] - **M&A Potential**: Certara has a strong balance sheet and is open to tuck-in acquisitions while also considering share repurchase as a capital allocation strategy [48][49] Conclusion - Certara is navigating a challenging market environment with a focus on operational improvements, strategic investments in AI and R&D, and leveraging its leadership position in biosimulation to drive future growth. The company is optimistic about stabilizing market conditions and the potential for increased demand in its services and software offerings [50][51]

Summary of Certara FY Conference Call (March 03, 2026) Company Overview - **Company**: Certara (NasdaqGS:CERT) - **Industry**: Biotechnology and Pharmaceutical Services Key Points and Arguments Leadership Transition - John Gallagher, the new CFO, has been in the role for approximately 61-62 days and is focused on transitioning from fact-finding to actionable solutions for business growth [7][8][9] - The management team expresses optimism about the company's potential and the quality of its products and personnel [8][9] Growth Drivers - Certara has several market-leading products with growth potential, particularly in the MIDD (Model-Informed Drug Development) and Biosimulation sectors, which constitute about two-thirds of the business [12][13] - The company aims to enhance operational execution and customer-centricity, focusing on strategic clarity and disciplined product management [14][15] Regulatory Services Business - There is ongoing discussion about the future of the Regulatory services business, with mixed opinions on whether to sell or retain it. The business has shown resilience despite market pressures [17][19][22] - The CFO noted a 1.5 book-to-bill ratio in December, indicating strong performance despite external pressures [18][19] Financial Outlook - For FY 2026, Certara expects flat to 4% growth in top-line revenues, with low single-digit growth anticipated for both software and services [32][34][36] - The company reported a strong EBITDA margin of 32% for the previous year and aims to maintain similar margins despite increased investments in growth areas [46][48] AI Integration and Innovation - Certara is embedding AI capabilities into its existing products, such as Phoenix Cloud and Certara IQ, which are expected to drive growth in the near term [50][52] - The company anticipates that AI will enhance both technology and service offerings, with a focus on customer adoption and integration [54][55] Regulatory Relationships - Certara has established strong relationships with over 20 regulators globally, which aids in facilitating communication between biopharma customers and regulatory bodies [30][31] - The company is optimistic about the positive regulatory environment and its potential to drive business growth [30] Future Catalysts - Key growth catalysts include the transition of tier 1 customers to the cloud version of Phoenix and developments in QSP (Quantitative Systems Pharmacology) [61][62] - Certara is exploring new metrics to better communicate its growth and value beyond traditional service versus software bookings [63][64] Additional Important Insights - The management emphasizes the importance of innovation and operational changes to leverage external partnerships effectively [58] - The company is focused on understanding customer needs and enhancing its offerings to meet those demands [56][57] This summary encapsulates the critical insights from the Certara FY Conference Call, highlighting the company's strategic direction, financial outlook, and growth opportunities within the biotechnology and pharmaceutical services industry.

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.6 million, representing a year-over-year growth of 3% on a reported basis and 2% on a constant currency basis [18] - For the full year 2025, total revenue was $418.8 million, reflecting a year-over-year growth of 9% on a reported basis and 8% on a constant currency basis [18] - Adjusted EBITDA for Q4 2025 was $32.5 million, a decrease from $33.5 million in Q4 2024, with an adjusted EBITDA margin of 31% [23] - Net loss for Q4 2025 was $5.9 million, compared to net income of $6.6 million in Q4 2024 [24] - Adjusted diluted earnings per share for Q4 2025 was $0.09, down from $0.15 in the same quarter last year [25] Business Line Data and Key Metrics Changes - Software revenue in Q4 2025 was $46.4 million, up 10% year-over-year, driven by MIDD software and Pinnacle 21 [19] - Services revenue for Q4 2025 was $57.3 million, down 1% year-over-year [21] - Software bookings in Q4 2025 were $56.1 million, down 6% from the prior year period [20] - MIDD services bookings saw double-digit growth in Q4, led by Tiers 2 and 3 [22] Market Data and Key Metrics Changes - The pharmaceutical industry is spending over $200 billion annually on drug development, with timelines extending to 10-15 years [7] - Certara has over 2,600 customers and 23 regulatory agencies using its technologies [9] Company Strategy and Development Direction - The company aims to sharpen operations, focus investments, and execute with greater discipline to capture market opportunities [6] - Certara plans to enhance AI integration and focus on core R&D technologies and model-informed drug development (MIDD) [15] - The company is undergoing a strategic review of its regulatory writing and operations business to maximize long-term shareholder value [13] Management's Comments on Operating Environment and Future Outlook - Management expects flat to low single-digit revenue growth for 2026, reflecting market conditions and planned operational improvements [16] - The company believes it can achieve double-digit growth over time, contingent on improved execution and market acceptance of its technologies [9][31] - Management is optimistic about the strengthening market and better-than-expected spending commitments from customers [46] Other Important Information - Certara repurchased approximately 3.3 million shares for $43 million during 2025 [25] - The company has identified approximately $10 million in cost avoidance for 2026 compared to prior planning [23] Q&A Session Summary Question: What attracted you to Certara and how do you view its differentiation? - The new CEO sees Certara as an undervalued gem with significant growth potential, given its strong market position and regulatory relationships [31][33] Question: How does the platform approach factor into the customer-centric strategy? - The CEO emphasized the importance of serving existing users while also enhancing engagement at senior levels to drive innovation [35] Question: Can you break down the revenue guidance for 2026? - The guidance reflects low single-digit growth due to stable end markets and a deceleration in software bookings [42] Question: What are the opportunities for AI enablement? - AI is being actively embedded into core assets, with a focus on enhancing both product offerings and operational efficiency [54][56] Question: What are the lowest hanging fruit in revamping the commercial organization? - Immediate focus areas include pricing, customer centricity, and optimizing relationships with clients [60]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.6 million, representing a year-over-year growth of 3% on a reported basis and 2% on a constant currency basis [18] - For the full year 2025, total revenue was $418.8 million, reflecting a year-over-year growth of 9% on a reported basis and 8% on a constant currency basis [18] - Adjusted EBITDA for Q4 2025 was $32.5 million, a decrease from $33.5 million in Q4 2024, with an adjusted EBITDA margin of 31% [23] - Net loss for Q4 2025 was $5.9 million, compared to net income of $6.6 million in Q4 2024 [24] - Adjusted diluted earnings per share for Q4 2025 was $0.09, down from $0.15 in the same period last year [25] Business Line Data and Key Metrics Changes - Software revenue in Q4 2025 was $46.4 million, up 10% year-over-year, driven by MIDD software and Pinnacle 21 [19] - Services revenue for Q4 2025 was $57.3 million, down 1% year-over-year [21] - Software bookings in Q4 2025 were $56.1 million, down 6% from the prior year period [20] - MIDD services bookings saw double-digit growth in Q4, led by Tiers 2 and 3 [22] Market Data and Key Metrics Changes - The pharmaceutical industry is spending over $200 billion annually on drug development, with timelines extending to 10-15 years [7] - Certara has over 2,600 customers and 23 regulatory agencies using its technologies [9] Company Strategy and Development Direction - The company aims to sharpen operations, focus investments, and execute with greater discipline to capture market opportunities [6] - Certara plans to enhance AI integration and focus on core R&D technologies and model-informed drug development (MIDD) [15] - The company is undergoing a strategic review of its regulatory writing and operations business to maximize long-term shareholder value [13] Management's Comments on Operating Environment and Future Outlook - Management expressed that 2026 will be a transition year with guidance for flat to low single-digit revenue growth, reflecting market conditions and planned operational improvements [16] - The company believes it can achieve double-digit growth over time, although current guidance reflects a cautious outlook due to market dynamics [9][87] Other Important Information - Certara repurchased approximately 3.3 million shares for $43 million during 2025 [25] - The company has identified approximately $10 million in cost avoidance for 2026 compared to prior planning [23] Q&A Session Summary Question: What attracted you to Certara and how do you view its differentiation? - The new CEO highlighted the significant market opportunity and the company's strong track record, viewing it as an undervalued gem with potential for growth [31] Question: How does the platform approach factor into the customer-centric strategy? - The CEO emphasized that the strategy remains focused on serving existing users while enhancing engagement at senior levels to drive innovation [36] Question: Can you break down the revenue guidance for 2026? - Management indicated that the guidance reflects low single-digit growth due to services performance and software bookings deceleration [42] Question: What are the opportunities for AI enablement? - The CEO noted that AI is being embedded into core assets and is seen as a major change agent for both product and operational efficiency [54] Question: What is the outlook for the regulatory writing business? - The CEO mentioned that a strategic review is underway, with a resolution expected soon, as the business has been compressing year-over-year [68]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.6 million, representing a year-over-year growth of 3% on a reported basis and 2% on a constant currency basis [19] - For the full year 2025, total revenue was $418.8 million, reflecting a year-over-year growth of 9% on a reported basis and 8% on a constant currency basis [19] - Adjusted EBITDA for Q4 2025 was $32.5 million, a decrease from $33.5 million in Q4 2024, with an adjusted EBITDA margin of 31% [24] - Net loss for Q4 2025 was $5.9 million, compared to net income of $6.6 million in Q4 2024 [25] - Adjusted diluted earnings per share for Q4 2025 was $0.09, down from $0.15 in the same quarter last year [26] Business Line Data and Key Metrics Changes - Software revenue in Q4 2025 was $46.4 million, up 10% year-over-year, driven by MIDD software and Pinnacle 21 [20] - Services revenue for Q4 2025 was $57.3 million, down 1% year-over-year [22] - Software bookings in Q4 2025 were $56.1 million, down 6% from the prior year period [21] - MIDD services bookings saw double-digit growth in Q4, with growth led by Tiers 2 and 3 [23] Market Data and Key Metrics Changes - The pharmaceutical industry is spending over $200 billion annually on drug development, with timelines extending to 10-15 years [6] - Certara has over 2,600 customers and 23 regulatory agencies using its technologies [9] Company Strategy and Development Direction - The company aims to sharpen operations, focus investments, and execute with greater discipline to capture market opportunities [5] - Certara plans to enhance AI integration and focus on core R&D technologies and model-informed drug development (MIDD) [16] - The company is undergoing a strategic review of its regulatory writing and operations business to maximize long-term shareholder value [13] Management's Comments on Operating Environment and Future Outlook - Management expressed that 2026 will be a transition year with guidance for flat to low single-digit revenue growth, reflecting market conditions and planned operational improvements [17] - The company believes it can achieve double-digit growth over time, although it did not provide a specific timeline [90] Other Important Information - Certara repurchased approximately 3.3 million shares for $43 million during 2025 [26] - The company has identified approximately $10 million in cost avoidance for 2026 compared to prior planning [24] Q&A Session Questions and Answers Question: What attracted you to Certara and how do you view the differentiation of its software products? - The new CEO highlighted the compelling market opportunity and the strong track record of Certara's software products being deeply embedded in customer workflows [32][34] Question: How does the platform approach and cross-selling factor into the customer-centric strategy? - The CEO emphasized that the strategy remains focused on serving existing users while enhancing engagement at senior levels to drive innovation [38] Question: Can you break down the revenue guidance for 2026? - Management indicated that the guidance reflects low single-digit growth due to stable end markets and a deceleration in software bookings [43] Question: What are the opportunities for AI enablement? - AI is being actively embedded into core assets, with a focus on enhancing product functionality and improving operational efficiency [54][58] Question: What are the lowest hanging fruit in revamping the commercial organization? - The CEO mentioned optimizing customer relationships, pricing, and operational elements as immediate areas of focus [62]

Summary of Certara FY Conference Call (November 18, 2025) Company Overview - **Company**: Certara (NasdaqGS:CERT) - **Industry**: Biopharmaceutical services and software Key Points Demand Environment - **Tier 3 Customers**: Strong performance noted in Tier 3 (biotech companies) with double-digit growth in biosim services, driven by a focus on well-funded biotech firms [3][4] - **Tier 1 Customers**: Weakness observed in Tier 1 (large pharma) customers due to delays in decision-making and project slowdowns, particularly in regulatory and biosim services [4][12] - **Q4 Expectations**: Anticipation of a strong Q4 with expected sequential increase in bookings, although not as pronounced as in previous years due to Tier 1 customer delays [5][10] Software vs. Services - **Software Stability**: Software business remains stable with high renewal rates and organic revenue growth of 6% year-to-date [7][27] - **Service Volatility**: Services are more volatile, influenced by broader market conditions, with a noted deceleration in bookings but solid revenue conversion from backlog [8][39] Regulatory Environment - **Impact on Business**: Mixed regulatory backdrop with fewer drug approvals impacting regulatory services, but positive sentiment from FDA directives on non-animal testing methodologies providing a tailwind [13][14] Cloud Strategy - **Certara Cloud Adoption**: Strong adoption of Certara Cloud, enhancing cross-sell opportunities as customers transition from desktop to cloud versions of software [15][16] - **Phoenix Cloud Launch**: Transitioning customers to the cloud version of Phoenix, which includes AI enhancements, is expected to drive growth [17][18] Financial Performance - **EBITDA Margins**: EBITDA margins stable to improving, with year-to-date gross margins near record levels. R&D expenses increased by 24% due to software investments [41][42] - **Net Revenue Retention (NRR)**: NRR at the lower end of expectations, driven by organic software revenue growth and pricing strategies [27][28] AI Integration - **AI in Products**: Certara has embedded AI into various software offerings, including Coauthor for regulatory writing and Certara IQ for quantitative systems pharmacology [30][31] - **Monetization of AI**: AI capabilities are being monetized through new product offerings and pricing strategies, with paying customers for AI products already in place [33] Services Demand - **Growth Areas**: QSP services are a highlight, with traditional PKPD services also growing. Regulatory consulting has seen weakness due to FDA uncertainties [36][37] - **Utilization Rates**: High utilization rates in the services team are expected to continue, providing revenue visibility despite booking volatility [39] M&A and Capital Deployment - **Acquisition Strategy**: Successful integration of Comaxon and Applied BioMath, with a focus on expanding capabilities in the biosimulation space [51][52] - **Future M&A Plans**: Certara aims to continue pursuing strategic acquisitions in software, balancing between M&A and share repurchase as capital deployment strategies [48][49] Long-term Outlook - **Growth Projections**: Expectation of double-digit growth in both software and services, with potential for margin expansion as growth rates increase [46] Customer Insights - **Insourcing vs. Outsourcing**: Customers are increasingly using AI internally, which may influence their decisions on outsourcing services to Certara [56][57] This summary encapsulates the key insights and developments discussed during the Certara FY Conference Call, highlighting the company's performance, market dynamics, and strategic initiatives.

Summary of Certara Conference Call Company Overview - **Company**: Certara - **Industry**: Pharmaceutical services supply chain, focusing on biosimulation and regulatory services Key Points Q3 Results and Market Reaction - Certara experienced a slowdown in bookings at the end of Q3, which alarmed the market [4] - The company had lower-than-expected bookings, particularly in the regulatory business, which has been volatile [5] - Despite the slowdown, Certara reported strong results with tier three biotech clients, indicating a successful strategy focusing on venture capital companies [4][6] Regulatory Business Review - The regulatory business has been under strategic review for over a year due to volatility and current disruptions at the FDA [8] - Certara expects the regulatory environment to stabilize by 2026, but the business is not considered strategically important as it once was [9][11] Biosimulation and Market Trends - Certara holds a leadership position in biosimulation, benefiting from FDA initiatives to reduce animal testing [12][15] - The company is seeing increased interest in biosimulation from clients, particularly in monoclonal antibody development [13][14] - Certara's QSP (Quantitative Systems Pharmacology) business is growing, with the launch of Certara IQ aimed at becoming a standard software product in the market [35] Service Bookings and Client Dynamics - Tier three services have been strong, while tier one clients showed a slowdown in service bookings [20] - Certara has focused on financial sponsors and larger VCs to stabilize its client base [21] - The company has a large backlog of work, indicating potential for future growth as the market recovers [22] Pricing Environment - The current pricing environment is weaker, with mid-single-digit pricing increases on software products being tempered [24] - Certara is prioritizing the growth of biosimulation usage over immediate price increases [24] Product Development and Innovation - Certara has expanded its software offerings, including new versions of Simcyp targeted at preclinical and formulation scientists [28][29] - The company is evolving its software portfolio into a cloud-based platform, with plans for further integration and AI enhancements by 2026 [39][41] Economic and Regulatory Pressures - Certara faces hesitancy from clients to spend due to uncertainties in the regulatory environment and macroeconomic factors [44] - Despite these challenges, there is a long-term trend towards increased interest in modeling as a cost-effective solution in pharma [45][46] Conclusion - Certara is navigating a complex environment with both challenges and opportunities, particularly in biosimulation and regulatory services, while maintaining a strong pipeline and backlog of work [22][23]

Financial Data and Key Metrics Changes - Q3 2025 revenue was $104.6 million, reflecting a 10% year-over-year growth [4][14] - Adjusted EBITDA for Q3 was $35.2 million, with a margin of 34% [4][18] - Q3 bookings totaled $96.6 million, representing a 1% increase year-over-year [5][14] - The company narrowed its revenue guidance for 2025 to $415-$420 million, indicating 8%-9% growth compared to 2024 [5][20] Business Line Data and Key Metrics Changes - Software revenue reached $43.8 million, growing 22% year-over-year, with organic growth of 6% [10][15] - Service revenue was $60.8 million, up 3% year-over-year, driven by growth in QSP services [11][17] - Software bookings of $40.8 million increased 17%, while service bookings declined 9% [10][17] Market Data and Key Metrics Changes - Tier 1 services customers exhibited cautious spending behavior, impacting deal timelines [5][6] - The adoption of biosimulation solutions is increasing among large pharma customers, particularly in model-informed drug development [6][8] Company Strategy and Development Direction - The company is focused on investing in R&D and commercial teams, with R&D spending up 24% year-over-year [4][11] - Certara is expanding its software capabilities into discovery and preclinical phases, enhancing its product offerings [9][30] - The strategic review of the regulatory services business is nearing completion, with a definitive outcome expected by the end of 2025 [12] Management's Comments on Operating Environment and Future Outlook - Management noted a slowdown in deal completion timelines, particularly in regulatory services, due to large pharma customers adjusting their R&D focus [6][12] - There are positive leading indicators for the biosimulation market, with expectations for continued growth in 2026 [6][20] - Management expressed cautious optimism regarding macroeconomic stability and its potential positive impact on customer spending [35][46] Other Important Information - The company completed the Chemaxon acquisition, which has contributed positively to revenue and is expected to reach corporate average margins by year-end [9][19] - The company has repurchased approximately $41 million of stock as part of a $100 million share repurchase program [19] Q&A Session Summary Question: What is the dynamic regarding tier one services revenue or bookings? - Management noted delays in decision-making among tier one customers, with expectations for some deals to close in Q4 and others pushed to 2026 [23][24] Question: Can you comment on the gross profit outperformance? - Management attributed gross margin improvement to productivity gains and a favorable mix shift towards software [25][26] Question: How is the growth of QSP expected to evolve? - The company aims to standardize QSP modeling through its new software platform, Certara IQ, which is expected to drive efficiency and financial benefits [27][30] Question: What is the outlook for tier two and tier three services? - Tier two and tier three services have shown good growth, partially offsetting the headwinds faced by tier one services [64][65] Question: How does the company view the impact of AI on its business? - Management sees AI as a significant opportunity, with increased willingness among customers to adopt AI-enabled products [41][42]